2018 / 05

DOI: 10.24075/brsmu.2018.068

ORIGINAL RESEARCH

Evaluation of the rivaroxaban-influenced effect of ABCB1 and CYP3A5 gene polymorphisms on prothrombin time in patients after total hip or knee replacement surgery

Sychev DA1, Minnigulov RM2, Ryzhikova KA1, Yudina IYu2, Lychagin AV2, Morozova TE2
About authors

1 Russian Medical Academy of Continuous Professional Education, Moscow

2 Sechenov First Moscow State Medical University, Moscow, Russia

Correspondence should be addressed: Radik M. Minnigulov
Bolshaya Pirogovskaya 2, build. 4, Moscow, 119435; moc.liamg@voluginnim.kidar

About paper

Funding: this study was supported by Russian Science Foundation, project 16-15-00227 “Conducting fundamental scientific research and exploratory research on priority thematic research areas”.

Acknowledgments: the authors would like to thank M. M. Bogdanov, practitioner with the Clinic of Traumatology, Orthopedics and Joint Pathology of the 1st Hospital of I. M. Sechenov First Moscow State Medical University, for his assistance in enlisting patients.

Received: 2018-10-08 Accepted: 2018-10-30 Published online: 2018-12-15
|
  1. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr et al. Prevention of venous thromboembolism. Chest. 2001; 119 (1): 132–75.
  2. Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation. 2004; 110 (24 Suppl 1): 4–12.
  3. Kavalerskij GM, Sereda AP, Murylev VJu, Rukin JaA, Gavrilov AV, Arhipov IV, i dr. 2D-planirovanie jendoprotezirovanija tazobedrennogo sustava. Travmatologija i ortopedija Rossii. 2015; 4 (78): 95–102.
  4. New Drug Application (NDA) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Xarelto® (rivaroxaban) 10 mg immediate release Tablets, for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients undergoing: hip replacement surgery or knee replacement surgery [Internet]. 2008 July [cited 2018 Aug 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022406s000ltr.pdf.
  5. European Medicines Agency. Doc.Ref.: EMEA/543519/2008. CHMP assessment report for Xarelto. [Internet]. 2008 [cited 2018 Aug 1]. Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Public_assessment_report/ human/000944/WC500057122.pdf.
  6. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004; 25 (8): 423–9.
  7. GeneCards: The Human Gene Database. ABCB1 Gene [Internet]. [cited 2018 Aug 1]. Available from: https://www.genecards.org/ cgi-bin/carddisp.pl?gene=ABCB1
  8. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005; 15 (10): 693–704.
  9. Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012; 22 (7): 555–8.
  10. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358 (26): 2765–75.
  11. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372 (9632): 31–9.
  12. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358 (26): 2776–86.
  13. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373 (9676): 1673–80.
  14. Instrukcija po medicinskomu primeneniju lekarstvennogo sredstva Ksarelto® v Rossijskoj Federacii. Registracionnyj nomer: LSR-009820/09.
  15. Online Encyclopedia for Genetic Epidemiology studies. Hardy- Weinberg equilibrium calculator [Internet]. [cited 2018 Dec 12]. Available from: http://www.oege.org/software/hwe-mr-calc.shtml
  16. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002; 359 (9300): 30–6.
  17. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS. 2003; 17 (11): 1696–8.
  18. Löscher W., Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther. 2002; 301 (1): 7–14.
  19. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003; 348 (15): 1442–8.
  20. Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004; 14 (8): 523–5.